Marketing-authorisation holder · Ireland
Mylan Ireland Limited
22 medicines in 4 countries, as authorisation holder.
Loading your page…
Loading your page…
Marketing-authorisation holder · Ireland
22 medicines in 4 countries, as authorisation holder.
One free account for the Prognia apps: Ward to study, Osler for clinical answers with their sources, and the network to find your colleagues.
Groups are put together by Prognia from the names regulators publish and from company links; they are not an official corporate structure.
Every medicine in the registers under its name, current ones first.
22 medicines
| Medicine | Substance | Country | Status | Authorised |
|---|---|---|---|---|
| ABIRATERONA MYLAN 1000 MG COMPRIMIDOS RECUBIERTOS CON PELICULA1000 mg · Comprimido recubierto con película | Abiraterone | Spain | Marketed | 2022 |
| ABIRATERONA MYLAN 500 MG COMPRIMIDOS RECUBIERTOS CON PELICULA EFG500 mg · Comprimido recubierto con película | Abiraterone | Spain | Authorised | 2022 |
| ARIXTRA10mg/0.8ml (10mg/0.8ml) | 2.5mg/0.5ml (2.5mg/0.5ml) | 5mg/0.4ml (5mg/0.4ml) | 7.5mg/0.6ml (7.5mg/0.6ml) · Solution | Fondaparinux | United States | Marketed | 2001 |
| AZACITIDINA MYLAN 25 MG/ML POLVO PARA SUSPENSION INYECTABLE EFG100 mg · Polvo para suspensión inyectable | Azacitidine | Spain | Marketed | 2020 |
| FINGOLIMOD MYLAN 0,5 MG CAPSULAS DURAS EFG0,56 mg · Cápsula dura | Fingolimod | Spain | Authorised | 2021 |
| FUMARATO DE DIMETILO MYLAN 120 MG CAPSULAS DURAS GASTRORRESISTENTES EFG120 mg · Cápsula dura gastrorresistente | Dimethyl | Spain | Marketed | 2024 |
| FUMARATO DE DIMETILO MYLAN 240 MG CAPSULAS DURAS GASTRORRESISTENTES EFG240 mg · Cápsula dura gastrorresistente | Dimethyl | Spain | Marketed | 2024 |
| LENALIDOMIDA MYLAN 10 mg CAPSULAS DURAS EFG10 mg · Cápsula dura | Lenalidomide | Spain | Marketed | 2021 |
| LENALIDOMIDA MYLAN 15 mg CAPSULAS DURAS EFG15 mg · Cápsula dura | Lenalidomide | Spain | Marketed | 2021 |
| LENALIDOMIDA MYLAN 20 mg CAPSULAS DURAS EFG20 mg · Cápsula dura | Lenalidomide | Spain | Marketed | 2021 |
| LENALIDOMIDA MYLAN 25 mg CAPSULAS DURAS EFG25 mg · Cápsula dura | Lenalidomide | Spain | Marketed | 2021 |
| LENALIDOMIDA MYLAN 5 mg CAPSULAS DURAS EFG5 mg · Cápsula dura | Lenalidomide | Spain | Marketed | 2021 |
| MIACALCIN100 IU/ML **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** | 200 IU/ML · Injectable | Calcitonin (salmon synthetic) | United States | Marketed | 1986 |
| PRETOMANID200mg · Tablet | Pretomanid | United States | Marketed | 2019 |
| SITAGLIPTINA/METFORMINA MYLAN 50 MG/1000 MG COMPRIMIDOS RECUBIERTOS CON PELICULA EFG1000 mg + 56,687 mg · Comprimido recubierto con película | Metformin, Sitagliptin | Spain | Marketed | 2022 |
| YUPELRI175mcg/3ml · Solution | Revefenacin | United States | Marketed | 2018 |
| Arsenic trioxide Mylan | Arsenicum album | EU (EMA) | Withdrawn | 2020 |
| Dimethyl fumarate Mylan | Dimethyl | EU (EMA) | Withdrawn | 2022 |
| Fingolimod Mylan | Fingolimod | EU (EMA) | Refused | 2021 |
| FUMARATO DE DIMETILO MYLAN 120 MG CAPSULAS DURAS GASTRORRESISTENTES EFG120 mg · Cápsula dura gastrorresistente | Dimethyl | Spain | Withdrawn | 2022 |
| FUMARATO DE DIMETILO MYLAN 240 MG CAPSULAS DURAS GASTRORRESISTENTES EFG240 mg · Cápsula dura gastrorresistente | Dimethyl | Spain | Withdrawn | 2022 |
| POSACONAZOL MYLAN 40 mg/ml40mg/ml · Susp. orala | Posaconazole | Romania | unknown |
Where it holds or makes medicines, with how many are current.
| Country | Medicines | Current | Past | Companies |
|---|---|---|---|---|
| Spain | 14 | 12 | 2 | CompaniesAll medicines |
| United States | 4 | 4 | 0 | CompaniesAll medicines |
| European Union (EMA) | 3 | 0 | 3 | CompaniesAll medicines |
| Romania | 1 | 0 | 1 | CompaniesAll medicines |
Also in the registers of France
The ATC groups most of its medicines belong to, largest first.
The active substances in most of its medicines.
How the registers spell it, normalised: legal forms, accents and capitals removed.
Compiled by Prognia from the public medicine and company registers below. Logos are not used.
Source: European Medicines Agency (EPAR data).
Licence: EMA reuse policy (source acknowledgement required)
Fuente de la información: AEMPS (CIMA).
Licence: AEMPS open data reuse with attribution
Source: U.S. FDA, Drugs@FDA / openFDA. FDA does not endorse this site.
Licence: Public domain (U.S. Government work)
Source: BDPM (ANSM, HAS, UNCAM).
Licence: Licence Ouverte v1.0
Fuente de la información: Agencia Española de Medicamentos y Productos Sanitarios www.aemps.gob.es; CIMA presentaciones, acquired 11 October 2026 UTC; each source response/update date retained.
Licence: AEMPS explicit public open-data reuse for citizens and companies; source attribution and update date required
Fuente de la información: Agencia Española de Medicamentos y Productos Sanitarios www.aemps.gob.es; CIMA medicamentos, acquired 11 October 2026 UTC; each source response/update date retained.
Licence: AEMPS explicit public open-data reuse for citizens and companies; source attribution and update date required
BDPM / ANSM, HAS and UNCAM; original URLs and each update date retained
Licence: BDPM exact Licence Ouverte v1.0 (October 2011)
Ministerul Sănătății, Catalogul public naţional al preţurilor, 18 iunie 2021, downloaded 2026-10-08 from data.gov.ro; CC BY 4.0; structured factual adaptation, code whitespace trimmed only where explicitly recorded.
Licence: Creative Commons Attribution 4.0 International (CC BY 4.0)
Report an error or request removalCorrections from the company itself are welcome.
Other companies in the same group.
Ranked by their number of medicines.